Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Authors:
- 24 November 2021
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 43 (7) , 1769-1779
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease characterized by destruction of lung parenchyma and deposition of extracellular matrix in interstitial and alveolar spaces. But known drugs for IPF are far from meeting clinical demands, validation of drug targets against pulmonary fibrosis is in urgent demand. Tyrosine kinase receptor DDRs has been considered as a potential therapeutic target for pulmonary fibrosis due to its pathological collagen binding property and the roles in regulating extracellular matrix remodeling. In this study we designed and synthesized a new indazole derivative XBLJ-13, and identified XBLJ-13 as a highly specific and potent DDRs inhibitor with anti-inflammation and anti-fibrosis activities. We first demonstrated that DDR1/2 was highly expressed in the lung tissues of IPF patients. Then we showed that XBLJ-13 potently inhibited DDR1 and DDR2 kinases with IC50 values of 17.18 nM and 15.13 nM, respectively. Among a panel of 34 kinases tested, XBLJ-13 displayed relatively high selectivity for DDRs with minimal inhibitory effect on PDGFR family and FGFR1, as well as Abl kinase that had high homology with DDRs. Extensive profiling of XBLJ-13 revealed that the new inhibitor had much lower toxicity than nintedanib and better pharmacokinetic properties in mice. Furthermore, pharmacodynamic evaluation conducted in bleomycin-induced pulmonary fibrosis mice showed that administration of XBLJ-13 (30, 60, 90 mg·kg−1·d−1, i.g.) for 12 days significantly and dose-dependently ameliorated lung inflammation and fibrosis. Together, this study confirms that DDRs kinase is a potential target for PF, Particularly, compound XBLJ-13 is a highly potent and specific DDRs inhibitor, along with good pharmacokinetics profiles, and preferable in vivo efficacy, suggesting that it is a potential candidate for the treatment of PF.Keywords
This publication has 20 references indexed in Scilit:
- Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?Trends in Molecular Medicine, 2016
- The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2015
- Collagen I enhances functional activities of human monocyte-derived dendritic cells via discoidin domain receptor 2Cellular Immunology, 2012
- Integrating mechanisms of pulmonary fibrosisJournal of Experimental Medicine, 2011
- Collagen I Induces Discoidin Domain Receptor (DDR) 1 Expression through DDR2 and a JAK2-ERK1/2-mediated Mechanism in Primary Human Lung FibroblastsJournal of Biological Chemistry, 2011
- Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinibEuropean Journal of Pharmacology, 2008
- Discoidin Domain Receptor 1 Null Mice Are Protected against Hypertension-Induced Renal DiseaseJournal of the American Society of Nephrology, 2006
- Discoidin Domain Receptor 1–deficient Mice are Resistant to Bleomycin-induced Lung FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Collagen Gel Contraction Assay2006
- Activation of Discoidin Domain Receptor 1 Isoform b with Collagen Up-Regulates Chemokine Production in Human Macrophages: Role of p38 Mitogen-Activated Protein Kinase and NF-κBThe Journal of Immunology, 2004